Patient perspectives on physician conflict of interest in industry-sponsored clinical trials for multiple sclerosis therapeutics

Andrew J. Solomon, Eran Klein, John R. Corboy, James L. Bernat

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Pharmaceutical industry financial support of physicians, physician practices, and academic departments involved in multicenter industry-sponsored clinical trials of novel therapeutic agents is a relatively new and infrequently acknowledged source of potential physician conflict of interest. Detailed disclosure of these relationships to study participants is not uniformly a part of informed consent and documentation practices. Objective: To understand attitudes of patients with multiple sclerosis concerning disclosure of potential physician-industry conflicts of interest created by clinical trials and how such disclosures may influence study participation Methods: An anonymous online instrument was developed. Results: 597 people with multiple sclerosis participated in the study. The study found that detailed disclosure of conflicts of interest is important to potential participants in industry-sponsored clinical trials for multiple sclerosis therapies and that the presence of these conflicts of interest may influence patients' decisions to participate in these studies. Conclusions: Findings from this study support a call for uniform guidelines regarding disclosure of physician-industry relationships to prospective research participants for industry-sponsored clinical trials.

Original languageEnglish (US)
Pages (from-to)1593-1599
Number of pages7
JournalMultiple Sclerosis
Volume21
Issue number12
DOIs
StatePublished - 2015

Fingerprint

Conflict of Interest
Disclosure
Multiple Sclerosis
Industry
Clinical Trials
Physicians
Therapeutics
Financial Support
Drug Industry
Informed Consent
Documentation
Guidelines
Research

Keywords

  • Clinical trials
  • Conflict of interest
  • Industrysponsored clinical trials
  • Multiple sclerosis
  • Professional conduct and ethics

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Patient perspectives on physician conflict of interest in industry-sponsored clinical trials for multiple sclerosis therapeutics. / Solomon, Andrew J.; Klein, Eran; Corboy, John R.; Bernat, James L.

In: Multiple Sclerosis, Vol. 21, No. 12, 2015, p. 1593-1599.

Research output: Contribution to journalArticle

@article{67368ce10dce40dd80d9c594b6d5eba9,
title = "Patient perspectives on physician conflict of interest in industry-sponsored clinical trials for multiple sclerosis therapeutics",
abstract = "Background: Pharmaceutical industry financial support of physicians, physician practices, and academic departments involved in multicenter industry-sponsored clinical trials of novel therapeutic agents is a relatively new and infrequently acknowledged source of potential physician conflict of interest. Detailed disclosure of these relationships to study participants is not uniformly a part of informed consent and documentation practices. Objective: To understand attitudes of patients with multiple sclerosis concerning disclosure of potential physician-industry conflicts of interest created by clinical trials and how such disclosures may influence study participation Methods: An anonymous online instrument was developed. Results: 597 people with multiple sclerosis participated in the study. The study found that detailed disclosure of conflicts of interest is important to potential participants in industry-sponsored clinical trials for multiple sclerosis therapies and that the presence of these conflicts of interest may influence patients' decisions to participate in these studies. Conclusions: Findings from this study support a call for uniform guidelines regarding disclosure of physician-industry relationships to prospective research participants for industry-sponsored clinical trials.",
keywords = "Clinical trials, Conflict of interest, Industrysponsored clinical trials, Multiple sclerosis, Professional conduct and ethics",
author = "Solomon, {Andrew J.} and Eran Klein and Corboy, {John R.} and Bernat, {James L.}",
year = "2015",
doi = "10.1177/1352458515569101",
language = "English (US)",
volume = "21",
pages = "1593--1599",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "12",

}

TY - JOUR

T1 - Patient perspectives on physician conflict of interest in industry-sponsored clinical trials for multiple sclerosis therapeutics

AU - Solomon, Andrew J.

AU - Klein, Eran

AU - Corboy, John R.

AU - Bernat, James L.

PY - 2015

Y1 - 2015

N2 - Background: Pharmaceutical industry financial support of physicians, physician practices, and academic departments involved in multicenter industry-sponsored clinical trials of novel therapeutic agents is a relatively new and infrequently acknowledged source of potential physician conflict of interest. Detailed disclosure of these relationships to study participants is not uniformly a part of informed consent and documentation practices. Objective: To understand attitudes of patients with multiple sclerosis concerning disclosure of potential physician-industry conflicts of interest created by clinical trials and how such disclosures may influence study participation Methods: An anonymous online instrument was developed. Results: 597 people with multiple sclerosis participated in the study. The study found that detailed disclosure of conflicts of interest is important to potential participants in industry-sponsored clinical trials for multiple sclerosis therapies and that the presence of these conflicts of interest may influence patients' decisions to participate in these studies. Conclusions: Findings from this study support a call for uniform guidelines regarding disclosure of physician-industry relationships to prospective research participants for industry-sponsored clinical trials.

AB - Background: Pharmaceutical industry financial support of physicians, physician practices, and academic departments involved in multicenter industry-sponsored clinical trials of novel therapeutic agents is a relatively new and infrequently acknowledged source of potential physician conflict of interest. Detailed disclosure of these relationships to study participants is not uniformly a part of informed consent and documentation practices. Objective: To understand attitudes of patients with multiple sclerosis concerning disclosure of potential physician-industry conflicts of interest created by clinical trials and how such disclosures may influence study participation Methods: An anonymous online instrument was developed. Results: 597 people with multiple sclerosis participated in the study. The study found that detailed disclosure of conflicts of interest is important to potential participants in industry-sponsored clinical trials for multiple sclerosis therapies and that the presence of these conflicts of interest may influence patients' decisions to participate in these studies. Conclusions: Findings from this study support a call for uniform guidelines regarding disclosure of physician-industry relationships to prospective research participants for industry-sponsored clinical trials.

KW - Clinical trials

KW - Conflict of interest

KW - Industrysponsored clinical trials

KW - Multiple sclerosis

KW - Professional conduct and ethics

UR - http://www.scopus.com/inward/record.url?scp=84985952541&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84985952541&partnerID=8YFLogxK

U2 - 10.1177/1352458515569101

DO - 10.1177/1352458515569101

M3 - Article

C2 - 25716879

AN - SCOPUS:84943654490

VL - 21

SP - 1593

EP - 1599

JO - Multiple Sclerosis

JF - Multiple Sclerosis

SN - 1352-4585

IS - 12

ER -